The CysLT1 receptor antagonist montelukast blocks bronchoconstriction induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2015 – The immunology of allergic airway disease Year: 2015
Anti-inflammatory effects of histamine H1 -receptor antagonist and leukotriene CysLT1 -receptor antagonist in patients with atopic asthma maintained on inhaled corticosteroids Source: Eur Respir J 2004; 24: Suppl. 48, 221s Year: 2004
Leukotriene receptor antagonist (LTRA) montelukast for the treatment of acute bronchiolitis in infants Source: Eur Respir J 2004; 24: Suppl. 48, 504s Year: 2004
Safety and efficacy of the inhaled pan-selectin antagonist bimosiamose in patients with COPD Source: Eur Respir J 2007; 30: Suppl. 51, 613s Year: 2007
The CysLT1 receptor antagonist montelukast inhibits mast cell activation induced by inhaled leukotriene E4 in subjects with asthma Source: International Congress 2016 – Clinical and molecular studies in asthma Year: 2016
Dose-response of leukotriene CysLT1 -receptor antagonist on nasal lysine-aspirin challenge in patients with aspirin-induced asthma Source: Eur Respir J 2004; 24: Suppl. 48, 585s Year: 2004
Comparison of add-on of leukotriene receptor antagonist vs. long-acting beta2-agonist on FeNO in asthmatic children on regular inhaled budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002
Tiotropium provides greater improvements in FEV1 than leukotriene receptor antagonists as add-on to ICS in adults with asthma: a systematic review Source: International Congress 2018 – New developments in the treatment of asthma Year: 2018
The combination of single-dose montelukast and loratadine on exercise-induced bronchospasm in children Source: Eur Respir J 2002; 20: 104-107 Year: 2002
Montelukast inhibits bronchoconstriction and gas exchange defects induced by leukotriene D4 challenge in asthma Source: Eur Respir J 2002; 20: Suppl. 38, 308s Year: 2002
Dose-related efficacy of GSK573719, a new long-acting muscarinic receptor antagonist (LAMA) offering sustained 24-hour bronchodilation, in COPD Source: Annual Congress 2011 - Bronchodilators in asthma and COPD Year: 2011
Clinical efficacy of leukotriene antagonist in patients with asthma and allergic rhinitis Source: Eur Respir J 2005; 26: Suppl. 49, 254s Year: 2005
Protective effect of cysteinyl leukotriene receptor antagonist montelukast in bleomycin induced pulmonary fibrosis Source: Eur Respir J 2007; 30: Suppl. 51, 111s Year: 2007
Repeated-dose pharmacokinetics of once-daily TD-4208, a long-acting muscarinic receptor antagonist (LAMA), in subjects with COPD Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014
Dual tachykinin NK1/NK2 antagonist DNK333 inhibits neurokinin A-induced bronchoconstriction in asthma patients Source: Eur Respir J 2004; 23: 76-81 Year: 2004
Dose reduction of inhaled corticosteroids under concomitant medication with montelukast in patients with asthma Source: Eur Respir J 2002; 20: 1080-1087 Year: 2002
Inhaled corticosteroids and leukotriene receptor antagonists induce protection against adenosine 5‘monophosphate induced bronchospasm in a synergic fashion Source: Annual Congress 2007 - Current issues in airway physiology, pharmacology and monitoring Year: 2007
Pharmacological agents used to treat asthma Source: ISSN=1025-448x, ISBN=1-904097-26-x, page=339 Year: 2003
Real-life use and impact of inhaled steroids (ICS) and leukotriene receptor antagonists (LTRA) monotherapy in children with asthma Source: Annual Congress 2010 - Paediatric asthma treatment and monitoring Year: 2010
Inhibition of the inhaled allergen challenge response by the CRTH2 antagonist OC000459 in patients with asthma Source: Annual Congress 2010 - Novel anti-inflammatory agents for airway disease Year: 2010